Yonkenafil hydrochloride is a novel phosphodiesterase type 5 (PDE5) inhibitor that effectively reduces cerebral infarction, neurological deficits, edema, and neuronal damage in the infarcted area; it may improve cognitive function by modulating neurogenesis and shows potential for research in Alzheimer's disease.